Icotinib Versus Placebo as Adjuvant Therapy in EGFR-mutant Lung Adenocarcinoma

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2014
The purpose of this study is to compare 3years of disease-free survival (DFS) of Icotinib and placebo in the treatment of patients who EGFR mutation-positive II-IIIA lung adenocarcinoma.
Epistemonikos ID: 4bfe0903c6eacf97592175e5993ae8e5abbfa610
First added on: May 11, 2024